Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)
25 April 2023 - 10:08PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
Report of Foreign Private Issuer
Pursuant to Rule 13a-16 or 15d-16
of the Securities Exchange Act of 1934
For the month of April 2023
Commission File Number: 001-37643
PURPLE BIOTECH LTD.
(Translation of registrant’s name into English)
4 Oppenheimer Street, Science Park, Rehovot
7670104, Israel
(Address of principal executive offices)
Indicate by check mark whether the registrant files or will file annual
reports under cover Form 20-F or Form 40-F.
Form 20-F ☒ Form
40-F ☐
On April 25, 2023, Purple Biotech Ltd. (the “Company” or
the “Registrant”) issued a press release, “Purple Biotech Debuts Scientific Advisory Board”,
which is attached hereto as Exhibit 99.1.
Incorporation by Reference
This
Report on Form 6-K, including all exhibits attached hereto, is hereby incorporated by reference into each of the Registrant’s Registration
Statement on Form S-8 filed with the Securities and Exchange Commission
on May 20, 2016 (Registration file number 333-211478), the Registrant’s
Registration Statement on Form S-8 filed with the Securities and Exchange Commission on June 6, 2017 (Registration file number 333-218538),
the Registrant’s Registration Statement on Form F-3, as amended, originally filed with the Securities and Exchange Commission
on July 16, 2018 (Registration file number 333-226195), the Registrant’s Registration Statement on Form S-8 filed with the Securities
and Exchange Commission on March 28, 2019 (Registration file number 333-230584), the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on September 16, 2019 (Registration file number 333-233795), the Registrant’s
Registration Statement on Form F-3 filed with the Securities and Exchange Commission on December 2, 2019 (Registration file number 333-235327),
the Registrant’s Registration Statement on Form F-3 filed with the Securities and Exchange Commission on May 13, 2020 (Registration
file number 333- 238229), the Registrant’s Registration Statement on Form S-8 filed with the Securities and Exchange Commission
on May 18, 2020 (Registration file number 333-238481), each of the Registrant’s Registration Statements on Form F-3 filed with the
Securities and Exchange Commission on July 10, 2020 (Registration file numbers 333-239807 and 333-233793), the Registrant’s Registration
Statement on Form S-8 filed with the Securities and Exchange Commission on April 4, 2022 (Registration file number 333-264107) and the
Registrant’s Registration Statement on Form F-3 filed
with the Securities and Exchange Commission on March 23, 2023 (Registration file number 333-270769), to be a part thereof from the date
on which this report is submitted, to the extent not superseded by documents or reports subsequently filed or furnished.
SIGNATURES
Pursuant to the requirements
of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
April 25, 2023 |
PURPLE BIOTECH LTD. |
|
|
|
By: |
/s/ Lior Fhima |
|
|
Lior Fhima |
|
|
Chief Financial Officer |
2
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Oct 2024 to Nov 2024
Kitov Pharma (NASDAQ:KTOV)
Historical Stock Chart
From Nov 2023 to Nov 2024